Google fiercepharma website for below:
“In approving Ojjaara in the first line, the FDA also considered a subgroup analysis of the failed SIMPLIFY-1 trial in patients with anemia.””Now, the FDA appears to think that Ojjaara doesn’t have to beat Jakafi to deserve a first-line nod. Miels said he views this
https://www.fiercepharma.com/pharma/pleasant-surprise-gsk-fda-approves-jak-drug-momelotinib-broader-blood-cancer-use as “a recognition there’s a very elegant mechanism at play.”
Yawn.
Google fiercepharma website for below:“In approving Ojjaara in...
-
- There are more pages in this discussion • 691 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |